NCT00771810View on ClinicalTrials.gov

Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
ThrombocytopeniaNeutropeniaLymphopeniaAnemia
Interventions
DRUG

TXA127

Once daily subcutaneous injection of 100 ug/kg

DRUG

TXA127

Once daily subcutaneous injection of 300 ug/kg

DRUG

Placebo

Once daily subcutaneous injection of placebo

Trial Locations (6)

11718

Schwartz Gynecologic Oncology, PLLC, Brightwaters

36604

University of Southern Alabama Mitchell Cancer Institute, Mobile

60612

Rush University Medical Center, Chicago

67208

Associates in Women's Health, Wichita

90033

USC - LAC Medical Center, Los Angeles

92868

University of California - Irvine, Chao Family Comprehensive Cancer Center, Orange

Sponsors
All Listed Sponsors
lead

Tarix Pharmaceuticals

INDUSTRY

NCT00771810 - Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer | Biotech Hunter | Biotech Hunter